HER2 negative breast cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 16 Jun 2026 04:02:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png HER2 negative breast cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Everolimus and Exemestane for Patients with Metastatic Breast Cancer https://clinicaltrials.eu/trial/study-on-everolimus-and-exemestane-for-patients-with-metastatic-breast-cancer/ Wed, 29 Apr 2026 15:04:38 +0000 https://clinicaltrials.eu/trial/study-on-everolimus-and-exemestane-for-patients-with-metastatic-breast-cancer/ This clinical trial is focused on studying the effects of a medication called everolimus in patients with metastatic breast cancer. Metastatic breast cancer is a type of breast cancer that has spread beyond the breast to other parts of the body. The study will use two forms of everolimus tablets, Verimmus and Everolimus Onkogen, which are taken orally. Another medication, exemestane, may also be used in the study. The purpose of the study is to explore how these treatments can affect the quality of life for patients with this condition.

Participants in the study will be divided into two groups, or “arms,” to receive different treatment plans. The study will last for about four months, during which the quality of life of the participants will be assessed using a specific test called the FACT-B quality of life test. This test helps to measure how the treatment impacts the daily life and well-being of the participants. The study will also look at other factors, such as the response rate to the treatment, the safety and side effects of the medications, and how the body processes the medication over time.

The trial aims to determine if there is a significant improvement in the quality of life for patients taking everolimus, and whether it is possible to safely increase the dose for some patients. The study will also monitor the occurrence and severity of any side effects experienced by participants. By the end of the study, researchers hope to gather valuable information that could help improve treatment options for people with metastatic breast cancer.

]]> Study of Pembrolizumab and Olaparib for Patients with Advanced HER2 Negative Breast Cancer and Specific Genetic Mutations https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-olaparib-for-patients-with-advanced-her2-negative-breast-cancer-and-specific-genetic-mutations/ Wed, 29 Apr 2026 15:02:33 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-olaparib-for-patients-with-advanced-her2-negative-breast-cancer-and-specific-genetic-mutations/ This clinical trial is focused on studying a type of breast cancer known as HER2-negative breast cancer. This type of cancer does not have high levels of a protein called HER2, which can promote the growth of cancer cells. The study is specifically looking at patients whose cancer cannot be removed by surgery or has spread to other parts of the body, known as metastatic breast cancer. Additionally, these patients have certain genetic changes, or mutations, in genes such as BRCA1 or BRCA2, which are known to increase the risk of breast cancer. Other genes being studied include ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, and XRCC2, as well as a condition called homologous recombination deficiency, which affects the way cells repair DNA.

The trial is testing a combination of two treatments: pembrolizumab and olaparib. Pembrolizumab is a type of medicine called a PD-1 inhibitor, which helps the immune system recognize and attack cancer cells. Olaparib is a PARP inhibitor, which helps prevent cancer cells from repairing themselves, leading to their death. The purpose of the study is to see how effective this combination is in treating the cancer. Participants will receive these treatments over a period of 27 weeks, and their response to the treatment will be monitored.

Throughout the study, researchers will observe how well the cancer responds to the treatment, how long the response lasts, and how long patients live without the cancer getting worse. They will also monitor any side effects or serious health issues that may occur. This information will help determine if the combination of pembrolizumab and olaparib is a beneficial treatment option for patients with this specific type of breast cancer.

]]> Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-fadraciclib-for-patients-with-advanced-solid-tumors-and-lymphoma/ Wed, 29 Apr 2026 15:00:59 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-fadraciclib-for-patients-with-advanced-solid-tumors-and-lymphoma/ This clinical trial studies the effects of fadraciclib (also known as CYC065) in people with various types of advanced cancers. The study focuses on several types of solid tumors and lymphoma, including endometrial cancer, ovarian cancer, biliary tract cancer, hepatocellular carcinoma, B-cell lymphoma, T-cell lymphoma, metastatic colorectal cancer, and different types of breast cancer.

The medication being tested, fadraciclib, is taken by mouth in tablet form. It belongs to a group of drugs called CDK2/9 inhibitors, which work by blocking certain proteins that help cancer cells grow. The study aims to find the best dose of the medication and determine how well it works in treating these different types of cancer.

During the study, participants take the medication either once or twice daily in 28-day cycles. The treatment continues as long as it is helping and the side effects are manageable. Throughout the study, doctors monitor the participants’ health and how their cancer responds to the treatment. This includes regular check-ups and various medical tests to ensure safety and track the effectiveness of the medication.

]]> Study of Pembrolizumab with Chemotherapy for Patients with HER2-Negative Inflammatory Breast Cancer https://clinicaltrials.eu/trial/study-of-pembrolizumab-with-chemotherapy-for-patients-with-her2-negative-inflammatory-breast-cancer/ Wed, 29 Apr 2026 14:58:25 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-with-chemotherapy-for-patients-with-her2-negative-inflammatory-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as HER2-negative inflammatory breast cancer. The study is investigating the effects of a treatment combination that includes Pembrolizumab, also known by its code name MK-3475, along with a chemotherapy regimen called EC-Paclitaxel. The purpose of the study is to evaluate how well this combination works in treating the cancer and to observe any potential side effects.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will take place over several months, during which participants will receive the treatment and be monitored for their response to it. The study aims to see if the cancer can be reduced or eliminated before surgery, which is known as a pathological complete response. Additionally, the study will assess the safety of the treatment by monitoring for any significant side effects.

The medications involved in this study include Pembrolizumab, Cyclophosphamide, Epirubicin, and Paclitaxel. These are commonly used in cancer treatment and work in different ways to target and destroy cancer cells. The study is designed to provide valuable information on the effectiveness and safety of this treatment combination for patients with HER2-negative inflammatory breast cancer.

]]> Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery https://clinicaltrials.eu/trial/study-on-palbociclib-with-endocrine-therapy-for-patients-with-hormone-receptor-positive-her2-negative-local-or-regional-recurrence-of-breast-cancer/ Wed, 29 Apr 2026 14:30:30 +0000 https://clinicaltrials.eu/trial/study-on-palbociclib-with-endocrine-therapy-for-patients-with-hormone-receptor-positive-her2-negative-local-or-regional-recurrence-of-breast-cancer/ This study focuses on patients with hormone receptor-positive, HER2-negative breast cancer who have experienced a return of cancer in the same area after previous treatment (known as isolated locoregional recurrence). The study will test whether adding the medication palbociclib (also known as IBRANCE) to standard hormone therapy works better than hormone therapy alone.

The main purpose is to determine if using palbociclib together with hormone therapy for 3 years can help prevent the cancer from returning compared to using only hormone therapy. Palbociclib belongs to a group of drugs called CDK4/6 inhibitors, which work by blocking certain proteins that help cancer cells grow.

During the study, patients will receive either palbociclib tablets or capsules (at doses of 75 mg, 100 mg, or 125 mg) along with their regular hormone therapy, or they will receive only hormone therapy. The treatment will continue for up to three years, and doctors will monitor how well the treatment works and check for any side effects.

]]> Study of Trastuzumab Deruxtecan for Patients with HER2-Low Breast Cancer and New or Worsening Brain Metastases https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-for-patients-with-her2-low-breast-cancer-and-new-or-worsening-brain-metastases/ Wed, 29 Apr 2026 14:29:07 +0000 https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-for-patients-with-her2-low-breast-cancer-and-new-or-worsening-brain-metastases/ This clinical trial is focused on studying a type of breast cancer known as HER2-low breast cancer, which has spread to the brain, a condition referred to as brain metastases. The study is investigating the effects of a treatment called Trastuzumab Deruxtecan, also known by its code name DS-8201a. This treatment is given as a solution through an intravenous infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to evaluate how effective this treatment is for patients with HER2-low breast cancer that has either been newly diagnosed or is progressing in the brain. Participants in the study will receive the treatment and be monitored over time to see how their cancer responds. The study will also include a comparison with a placebo to better understand the treatment’s effects. The trial will last for a period of time, during which participants will have regular check-ups and assessments to track their progress and any changes in their condition.

Throughout the study, the focus will be on understanding the treatment’s impact on the cancer in the brain, as well as any side effects or changes in the participants’ quality of life. The study aims to provide valuable information that could help improve treatment options for patients with this specific type of breast cancer. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

]]> Study on Olaparib for Patients with Advanced HER2-Negative Breast Cancer and Specific Genetic Mutations https://clinicaltrials.eu/trial/study-on-olaparib-for-patients-with-advanced-her2-negative-breast-cancer-and-specific-genetic-mutations/ Wed, 29 Apr 2026 14:28:50 +0000 https://clinicaltrials.eu/trial/study-on-olaparib-for-patients-with-advanced-her2-negative-breast-cancer-and-specific-genetic-mutations/ This clinical trial is focused on studying the effectiveness of a medication called olaparib, also known by its code name AZD-2281, in treating certain types of breast cancer. The study involves patients with HER2-negative breast cancer that is either locally advanced, meaning it has spread to nearby tissues, or metastatic, meaning it has spread to other parts of the body. Specifically, the trial is looking at patients with mutations in genes such as BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, or those with a low score on a test called the RAD51-foci test.

The purpose of the study is to see if the RAD51-foci score can predict how well olaparib works in treating these types of breast cancer. Participants in the trial will receive olaparib in the form of film-coated tablets, which are taken orally. The study will compare the effects of olaparib with a placebo to determine its effectiveness. The trial will monitor the overall response rate, which measures how many patients experience a reduction in cancer size, and progression-free survival, which is the time during which the cancer does not get worse.

Throughout the study, participants will undergo regular check-ups and assessments to track their response to the treatment. The trial aims to provide valuable information on whether olaparib can be an effective treatment option for patients with these specific genetic mutations or test results. The study is expected to continue until August 2025, with recruitment having started in April 2022.

]]> Study of Milademetan and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer with GATA3 Mutation, ER-Positive, HER2-Negative https://clinicaltrials.eu/trial/study-of-milademetan-and-fulvestrant-for-patients-with-advanced-or-metastatic-breast-cancer-with-gata3-mutation-er-positive-her2-negative/ Wed, 29 Apr 2026 14:24:13 +0000 https://clinicaltrials.eu/trial/study-of-milademetan-and-fulvestrant-for-patients-with-advanced-or-metastatic-breast-cancer-with-gata3-mutation-er-positive-her2-negative/ This clinical trial is focused on studying a type of breast cancer known as GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer. The study involves two treatments: Milademetan, which is taken as a capsule, and Fulvestrant, which is given as an injection. The purpose of the study is to determine how effective these treatments are when used together in patients with this specific type of breast cancer.

Participants in the study will receive either the combination of Milademetan and Fulvestrant or a placebo. The study will last for several months, during which time participants will take the medication and have regular check-ups to monitor their health and the progress of the treatment. The study aims to see if the combination of these treatments can help control the cancer for at least six months.

Throughout the study, doctors will assess the participants’ response to the treatment, looking for any changes in the cancer’s size or spread. They will also monitor for any side effects that may occur. The study will help researchers understand if this combination of treatments can provide a clinical benefit to patients with this type of breast cancer.

]]> Study on Preoperative Treatment for HER2-Negative Breast Cancer Using Pembrolizumab, Paclitaxel, and Carboplatin in Patients Not Responding to Initial Chemotherapy https://clinicaltrials.eu/trial/study-on-preoperative-treatment-for-her2-negative-breast-cancer-using-pembrolizumab-paclitaxel-and-carboplatin-in-patients-not-responding-to-initial-chemotherapy/ Wed, 29 Apr 2026 14:24:04 +0000 https://clinicaltrials.eu/trial/study-on-preoperative-treatment-for-her2-negative-breast-cancer-using-pembrolizumab-paclitaxel-and-carboplatin-in-patients-not-responding-to-initial-chemotherapy/ This clinical trial is focused on studying a type of breast cancer known as HER2-negative breast cancer. The study is investigating the effectiveness and safety of combining a specific type of immunotherapy with radiation therapy and standard chemotherapy. The immunotherapy being tested is called pembrolizumab, which is compared to a placebo. Pembrolizumab is a medication that helps the immune system fight cancer cells. The trial aims to see if this combination can improve treatment outcomes for patients whose cancer has not responded well to initial chemotherapy.

Participants in the study will receive a combination of treatments before surgery. This includes a boost of radiation therapy, a short course of immunotherapy with either pembrolizumab or a placebo, and standard chemotherapy. The chemotherapy drugs used in this study include paclitaxel and carboplatin, which are commonly used to treat breast cancer. The study will monitor how well the cancer responds to these treatments and assess any side effects experienced by the participants.

The trial is designed to help researchers understand if adding pembrolizumab to the treatment plan can lead to better outcomes for patients with HER2-negative breast cancer. The study will also evaluate the quality of life of participants and the time it takes for the cancer to return, if it does. By comparing the results of those receiving pembrolizumab with those receiving a placebo, the study aims to provide valuable insights into the potential benefits of this treatment approach.

]]> Study on Irinotecan for Brain Metastases in Patients with HER2-Negative Breast Cancer https://clinicaltrials.eu/trial/study-on-irinotecan-for-brain-metastases-in-patients-with-her2-negative-breast-cancer/ Wed, 29 Apr 2026 14:23:06 +0000 https://clinicaltrials.eu/trial/study-on-irinotecan-for-brain-metastases-in-patients-with-her2-negative-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as HER2-negative metastatic breast cancer, which has spread to the brain. The study is investigating the effects of a treatment called nal-IRI, which is a form of the drug irinotecan. This medication is given as an infusion, meaning it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate how effective and safe nal-IRI is for patients whose cancer has progressed in the brain despite previous treatments like whole-brain radiation therapy or surgery.

Participants in the study will receive the nal-IRI treatment and will be monitored to see how their brain metastases respond. The study will look at whether the cancer in the brain shrinks or disappears, and how long any positive effects last. The trial will also assess the overall health and safety of the participants while they are receiving the treatment. The study is designed to gather information over a period of time to understand the potential benefits and risks of using nal-IRI for this specific type of breast cancer.

Throughout the study, medical professionals will use specific criteria to measure the response of the brain metastases to the treatment. These criteria help ensure that the results are consistent and reliable. The trial aims to provide valuable insights into whether nal-IRI can be a beneficial treatment option for patients with HER2-negative metastatic breast cancer that has spread to the brain.

]]> Study on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse https://clinicaltrials.eu/trial/study-on-the-impact-of-fluoroestradiol-f-18-pet-on-treatment-for-patients-with-er-her2-metastatic-breast-cancer-after-first-line-hormone-therapy-relapse/ Wed, 29 Apr 2026 14:22:44 +0000 https://clinicaltrials.eu/trial/study-on-the-impact-of-fluoroestradiol-f-18-pet-on-treatment-for-patients-with-er-her2-metastatic-breast-cancer-after-first-line-hormone-therapy-relapse/ This clinical trial is focused on studying the impact of a special imaging technique on the treatment of patients with a specific type of breast cancer. The disease being studied is metastatic breast cancer, which means the cancer has spread to other parts of the body. The patients involved in this study have breast cancer that is estrogen receptor-positive (ER+) and HER2-negative. This means their cancer cells grow in response to the hormone estrogen but do not have an excess of the HER2 protein. The patients have experienced a return of cancer after their initial treatment, which included hormone therapy.

The treatment being tested in this study is called FLUOROESTRADIOL F-18, also known by the code name EstroTep. This is a solution that is injected into the body and used in a type of imaging called Positron Emission Tomography (PET). The purpose of the study is to see how this imaging technique can help doctors make better treatment decisions for patients whose cancer has returned after the first line of treatment. The study will involve patients undergoing a PET scan with FLUOROESTRADIOL F-18 to help guide their future treatment options.

Throughout the study, patients will receive the PET scan and their doctors will use the results to decide on the best course of treatment. This may involve changes to their current treatment plan, such as adjusting hormone therapy or adding other treatments like chemotherapy or radiotherapy. The study aims to understand how this imaging technique can improve the management of metastatic breast cancer and help doctors make more informed decisions about patient care.

]]>